Evidence map›Paper›PMID 38639563›Full record

SynthesisImmunity, inflammation and disease2024

Biomarker role of maternal soluble human leukocyte antigen G in pre-eclampsia: A meta-analysis.

Abhinav Bhattarai, Sangam Shah, Krishna Dahal, Raksha Neupane, Sangharsha Thapa, Niraj Neupane, Joshuan J Barboza, Anisha Shrestha, Ranjit Sah, Vasso Apostolopoulos

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Immunity, inflammation and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 5 countries.

Abhinav BhattaraiInstitute of Medicine, Tribhuvan University, Maharajgunj, Nepal.
Sangam ShahInstitute of Medicine, Tribhuvan University, Maharajgunj, Nepal.ORCID 0000-0002-8203-3329
Krishna DahalInstitute of Medicine, Tribhuvan University, Maharajgunj, Nepal.ORCID 0000-0002-4137-1022
Raksha NeupaneInstitute of Medicine, Tribhuvan University, Maharajgunj, Nepal.
Sangharsha ThapaDepartment of Neurology, Westchester Medical Center, Valhalla, New York, USA.
Niraj NeupaneRochester General Hospital, Rochester, New York, USA.
Joshuan J BarbozaVicerrectorado de Investigacion, Universidad Norbert Wiener, Lima, Peru.
Anisha ShresthaInstitute of Medicine, Tribhuvan University, Maharajgunj, Nepal.
Ranjit SahDepartment of Microbiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.ORCID 0000-0002-2695-8714
Vasso ApostolopoulosInstitute for Health and Sport, Immunology and Translational Research, Victoria University, Melbourne, Victoria, Australia.
Tribhuvan University Teaching Hospital · NPAustralian Institute for Musculoskeletal Science · AUDr. D. Y. Patil Medical College, Hospital and Research Centre · INRochester General Hospital · USUniversidad Norbert Wiener · PEWestchester Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHuman leukocyte antigen-G (HLA-G) is a non-classical class I HLA molecule shown to regulate the immunomodulation of maternal immune cells to prevent fetal tissue destruction. Low levels of freely circulating maternal soluble HLA-G (sHLA-G) have been observed in pre-eclampsia, however, no pooled evidence exists. This meta-analysis aimed to generate pooled findings on the association of sHLA-G levels with pre-eclampsia and is the first study to perform a trimester-wise comparison of the levels of sHLA-G in preeclamptic cases and normal pregnant controls.

methodsThe databases PubMed, Emba, Web of Science, and Google Scholar through May 31, 2023. Preeclamptic women were defined as cases and normal pregnancies as controls. Data on the level of sHLA-G in cases and controls was extracted and subjected to a meta-analysis using a random-effects model. The pooled effect was expressed in terms of standardized mean difference (SMD). Sensitivity analysis was performed to investigate the effect of the exclusion of each study on the pooled results. Publication bias was assessed statistically.

resultsNine studies with altogether 567 PE cases and 1132 normal pregnancy controls were included in the meta-analysis. The first and third trimester levels of sHLA-G in PE cases were significantly lower than that of normal pregnant controls: (SMD: -0.84 [-1.29; -0.38]; p = .003; I

conclusionAlthough we found that first and third-trimester sHLA-G levels in pre-eclampsia are significantly lower, taking into consideration the inconsistent results from the sensitivity analysis, our findings advocate the demand for more studies with larger sample sizes to generate solid ground pooled evidence on the predictive role of sHLA-G in pre-eclampsia.

Indexed as

Pre-EclampsiaBiomarkersFemaleFetusHLA-G AntigensHumansPregnancyBiomarkersHLA-G Antigensbiomarkerhuman leukocyte antigen Gpre‐eclampsiasHLA‐G

Identifiers

PMID38639563
PMCPMC11027746
OpenAlexW4394942512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.